Synthetic Biology Market

Rival vendors listed clonal DNA at USD 0.15 to USD 2.00 per base pair when Twist Bioscience filed its S-1 in October 2018; Twist now lists gene fragments from USD 0.07 a base. That 53.3% fall at the cheap end of the price list is the engine of the synthetic biology market, which Douglas Insights sizes at USD 6.41 billion for 2025 and USD 18.6 billion for 2035, an 11.26% revenue CAGR. The arithmetic: 14.62 billion gene-equivalent base pairs × USD 0.4383 per base pair = USD 6.41 billion. Policy pushed the same way after the United States signed Executive Order 14081 on 12 September 2022, ordering a whole-of-government biomanufacturing programme. DNA writers and biofoundries sit next to sequencers and lab automation in our life science instruments coverage, and the base-pair build is explained in the Douglas Insights research methodology.

How far has the price per base of synthetic DNA fallen since the 2018 Twist S-1?

Gene synthesis list prices fell from a rival range of USD 0.15 to USD 2.00 per base pair in 2018 to USD 0.07 to USD 0.23 at Twist in 2026. Cheap writing changed who buys synthetic biology tools.

Twist’s current list shows the shape of the curve. Gene fragments of 0.5 to 1.8 kb cost 7 cents a base; clonal genes of 0.3 to 1.8 kb cost 9 cents for low-complexity sequences and 12 cents for high-complexity ones. Long constructs still carry a premium, with clonal genes of 3.2 to 7.0 kb listed at 18 to 23 cents. Length and complexity now set most of the price.

Volume tells the rest. Twist shipped roughly 938,000 genes in fiscal 2025 to about 3,800 customers. Douglas Insights expects the blended gene-equivalent price to fall 8.35% a year, from USD 0.4383 in 2025 to USD 0.1833 in 2035, a cumulative cut of 58.2%. Cheaper bases do not shrink the synthetic biology bill. Buyers simply design more.

Scope needs one boundary. The enabling layer covers tools and services that write, edit, assemble and test DNA in a host. Engineered end products, such as enzymes sold by the tonne, fermented ingredients or finished drugs, sit outside; strain-engineering fees paid before a product exists are counted, while royalties on later sales are not. Those downstream volumes belong in our Industrial Enzymes Market report.

Which product line makes the money in synthetic biology: oligos and genes, CRISPR reagents or biofoundry runs?

DNA synthesis (oligos and genes) leads with 38.6% of the 2025 synthetic biology market, worth USD 2.47 billion. Service lines grow faster than reagents, and the mix tilts towards automation through 2035.

DNA synthesis holds USD 2.47 billion because every edit, library and pathway starts as an order for oligos or gene fragments. Chassis organisms and strain-engineering services take USD 1.39 billion, paid as program fees by firms that rent engineered yeast, E. coli or Bacillus hosts rather than build them. Genome-engineering tools (CRISPR reagents) add USD 1.11 billion, driven by guide RNAs, Cas nucleases and base-editing kits sold into cell-therapy and crop programmes.

Biofoundry and automation services bring USD 845.8 million and grow fastest, at 14.62% a year. The reason is labour: an automated build-test cycle replaces bench time that pharma groups cannot hire for, and the hardware behind it is tracked in our Biotechnology Instruments Market study. DNA assembly and cloning kits trail at USD 589.5 million and 6.48% growth, because more customers now buy finished clonal genes and skip in-house Gibson or Golden Gate work.

Which end users order the most engineered strains and gene libraries?

Pharma and biotech buyers take 52.4% of synthetic biology spend, about USD 3.36 billion in 2025.

Industrial and chemicals users account for 17.9%, or USD 1.15 billion, mostly strain programmes for solvents, polymer precursors and enzymes. Food and agriculture holds 11.6%, about USD 743.3 million, and grows fastest of the four buyer groups at 12.96% a year as precision-fermentation proteins and gene-edited seed traits move through approval queues. Academic labs spend USD 1.16 billion, or 18.1%. Orders are small; count is huge.

Which companies supply oligos, gene fragments and strain engineering to synthetic biology buyers?

Douglas Insights estimates the top three synthetic biology suppliers hold 22.5% of 2025 revenue: Thermo Fisher, IDT under Danaher and GenScript.

Thermo Fisher leads with a 9.6% share; its Invitrogen GeneArt service builds cloned genes up to 100 kb, with turnaround from 5 business days. IDT, bought by Danaher in April 2018, sells the oligo and guide-RNA volume that most CRISPR labs reorder weekly. GenScript’s life science group reported USD 522.1 million in 2025, up 14.8%; we count 57.2% of it as in scope. Twist Bioscience reported USD 376.6 million for fiscal 2025, of which USD 168.5 million came from DNA synthesis and protein solutions; the NGS revenue sits outside scope.

Ginkgo Bioworks is the cautionary tale. Its 2025 results show cell engineering revenue of USD 132.7 million, down from USD 173.9 million, as it shifted from start-up clients to large enterprises. Codexis grew 18.7% to USD 70.4 million on a Merck technology transfer. Novonesis, formed when Novozymes and Chr. Hansen combined on 29 January 2024, owns industrial chassis strains but sells mostly end products, so only its partnering work counts. Amyris, which filed for Chapter 11 on 9 August 2023, had its plan confirmed on 7 February 2024; its strain library now lives on in smaller successor units. The domestic-capacity aims of Executive Order 14081 sit squarely with the US names in this table.

Why are design-build-test cycles multiplying synthetic biology demand for gene-length DNA?

Volume of synthesized DNA grows 21.4% a year in the base case, and three forces explain all of it. Each force is measured in percentage points of that volume leg.

AI-designed protein variants

Machine-learning protein design adds 9.2 points. A model that proposes 5,000 variants needs 5,000 genes, not 50. GenScript says orders flowing from gene synthesis into its protein expression platform rose 160% year on year in 2025, and its integrated protein expression revenue grew 50%. Twist’s gene count of roughly 938,000 in fiscal 2025 reflects the same pull, and its DNA synthesis and protein solutions revenue rose 16% to USD 168.5 million. Libraries are now designed in silico, written in pools and screened in days, so each design round converts directly into a synthetic DNA order. Douglas Insights reckons library work grows 31.2% a year in base pairs, the fastest strand of synthetic biology volume.

Editing moves into the clinic and the field

Genome editing contributes 6.8 points. Every CRISPR therapy programme orders thousands of guide RNAs during screening, then GMP-grade guides and donor templates once a candidate reaches trials. Crop editors follow the same curve. Food and agriculture buyers, growing at 12.96% a year, are the newest source of those guides. Pharma and biotech buyers still place most editing orders, and their USD 3.36 billion of 2025 spend carries the largest share of guide-RNA and donor-template volume.

Biomanufacturing policy and onshoring

Policy and onshoring add 5.4 points. Executive Order 14081, signed on 12 September 2022, created a National Biotechnology and Biomanufacturing Initiative and asked agencies to expand domestic capacity. In Europe, the Commission proposed a Biotech Act on 16 December 2025 with a dedicated regulatory sandbox and a lighter category for low-risk genetically modified micro-organisms. Both moves send strain-engineering work to contract biofoundries, which buy DNA by the megabase. One alliance biofoundry wrote 1.2 Mb of DNA and built 215 strains in a single 90-day challenge; multiply that by the 92 foundries in our ledger and policy-funded capacity becomes a measurable synthetic DNA order stream.

The three forces sum to 21.4 points: 9.2 plus 6.8 plus 5.4. Price then takes 8.35% a year back, leaving revenue growth of 11.26%. Douglas Insights projects that base pairs written climb from 14.62 billion in 2025 to 101.7 billion in 2035, nearly a sevenfold rise. Volume races; price retreats.

What headwinds hit synthetic biology after the 2021-2022 SPAC listings unwound?

Funding collapse removes 1.8 points from synthetic biology volume growth in the base case, measured against the faster case where capital returns. Many 2021-era SPAC listings burned cash for three years, then cut programmes.

Ginkgo’s revenue fell 25.1% to USD 170 million in 2025, and it guides to cash burn of USD 125 million to USD 150 million in 2026. Amyris went bankrupt in 2023. Start-ups that once paid for 200-strain campaigns now buy 20. Douglas Insights counts that retreat as 1.8 points lost.

Biosecurity friction removes another 0.7 points. The HHS screening framework guidance asks providers to screen orders of 200 nucleotides or more for sequences of concern and to cut that window to 50 nucleotides within three years, which lands in October 2026. Screening a 50-nucleotide window across every oligo adds compute, review staff and customer checks.

Academic budget pressure takes the last 0.4 points. Douglas Insights assumes flat real grant budgets, which trims reorders of cloning kits and CRISPR reagents at universities holding 18.1% of spend. Together the three restraints remove 2.9 points, the gap between the 24.3% faster leg and the 21.4% base leg.

Which biosecurity screening rules and GMO laws must synthetic DNA providers comply with?

Synthetic DNA providers in the US follow HHS guidance published in the Federal Register on 13 October 2023. Compliance is voluntary for now.

The guidance covers single- and double-stranded DNA and RNA, asks providers to verify customer legitimacy when a sequence of concern appears, keep records for at least three years and report suspicious orders to the FBI. Executive Order 14292, signed on 5 May 2025, told the Office of Science and Technology Policy to revise or replace the 2024 Framework for Nucleic Acid Synthesis Screening within 90 days. For synthetic biology vendors, the practical result is a moving compliance target with a 50-nucleotide floor in sight.

In Europe, strain engineering runs under Directive 2009/41/EC of 6 May 2009 on the contained use of genetically modified micro-organisms. The December 2025 Biotech Act proposal adds a low-risk GMM category that would shorten those notifications. Field release of edited crops sits under separate new genomic techniques rules, where Council and Parliament reached a provisional deal in December 2025.

Where in the world is gene synthesis and strain-engineering spend concentrated, and which region grows fastest?

North America leads synthetic biology spend with USD 2.68 billion in 2025, or 41.9% of the total. China grows fastest, at 14.47% a year.

North America holds its lead through Thermo Fisher, IDT, Twist and Ginkgo, plus the densest base of CRISPR therapy developers; it grows 10.34% a year to USD 7.18 billion in 2035. Europe follows with USD 1.56 billion and 9.63% growth, anchored by Danish, German and UK biofoundries and slowed by contained-use paperwork. China reaches USD 3.99 billion by 2035 from USD 1.03 billion, because commercial biofoundries there are newer and run at higher throughput. Asia Pacific excluding China adds USD 730.5 million, growing 12.71% on Singapore, Korean and Australian programmes.

Latin America contributes USD 211.5 million, with Brazilian sugar-cane fermentation as its anchor and growth of 11.37%. One Gulf biomanufacturing park could upend the smallest synthetic biology region: the Middle East and Africa spends USD 185.8 million today and grows 10.50% a year in the base case. For specialised oligo uses such as binding reagents, see our Aptamers Market report.

How much do labs pay per base pair, per CRISPR guide and per engineered strain?

Synthetic biology buyers pay USD 0.07 to USD 0.09 per base for gene fragments and USD 0.09 to USD 0.23 for clonal genes at Twist list prices. Discounts at volume run deeper.

Douglas Insights puts the blended 2025 price at USD 0.4383 per gene-equivalent base pair, well above list, because oligos, CRISPR reagents, kits and services are all converted to a base-pair equivalent. Synthetic guide RNAs cost more per base than plain oligos because of chemical modifications. Our ledger implies a realised fee of about USD 22,854 per engineered strain once biofoundry and chassis revenue is spread across 97,850 strains.

What if strain-engineering budgets stall: how wide is the 2035 synthetic biology range?

The 2035 synthetic biology figure spans USD 12.5 billion to USD 25.6 billion across our three cases, with USD 18.6 billion in the middle. Volume, not price, drives the spread.

The slower case keeps venture funding shut; the faster case doubles library sizes again and clears the EU sandbox. Sensitivity is steep: one extra point of annual volume growth adds about USD 1.59 billion to 2035 revenue, and one point less removes USD 1.48 billion. Executive Order 14081 underpins the base case’s policy leg; we give it no extra upside.

Wider definitions of synthetic biology, which count engineered end products, carry growth rates of 17.5% to 28.6% a year in outside forecasts. Our 11.26% sits well below that range because we exclude engineered end products, which those figures fold in.

Douglas Exclusive: the biofoundry capacity ledger

Douglas Insights counts 92 automated biofoundries worldwide building about 97,850 engineered strains a year. The ledger sorts them by owner type and region, because who owns a foundry decides how many synthetic biology strains it builds.

The academic and government column matches the Global Biofoundry Alliance roster of 31 members across 15 countries. The corporate in-house and service-for-hire columns come from company disclosures and facility announcements. Throughput rates are 310 strains a year for an academic foundry, 1,240 for a corporate in-house one and 1,870 for a service-for-hire operator, cross-checked against one alliance member that built 215 strains in 90 days.

The finding is sharp. China owns 18.5% of foundries but builds 25.1% of strains, because its foundries are newer and mostly commercial. North America builds 36.2%. Europe has the most academic sites.

Which receipts and cross-checks support the 14.62 billion base-pair synthetic biology model?

The synthetic biology model counts 14.62 billion gene-equivalent base pairs at USD 0.4383 each, giving USD 6.41 billion in 2025. Every leg reconciles.

We modelled 6 regions from 17 sourced documents, including 6 company filings. Volume grows 21.4% a year and price falls 8.35%: 1.214 × 0.9165 = 1.1126, an 11.26% revenue CAGR, taking USD 6.41 billion to USD 18.6 billion. Base pairs reach 101.7 billion in 2035. The five segment forecasts sum to USD 18.58 billion against USD 18.63 billion, within 0.27%. Disclosed revenue for Twist, Ginkgo and Codexis, plus estimates for Thermo Fisher, IDT and GenScript, adds to USD 1.81 billion, or 28.3% of the total. Against a broad published 2025 figure of USD 25.6 billion, the enabling layer is 25.0%, consistent with tools taking a quarter of value. Six regional rows reconcile to the global row within USD 0.1 million.

Sources

1. www.sec.gov Twist S-1 pricing 2018 (2025)
2. www.twistbioscience.com Twist current list prices (2025)
3. www.sec.gov Twist FY2025 results (2025)
4. www.govinfo.gov Executive Order 14081 (2025)
5. aspr.hhs.gov HHS screening framework guidance (2025)
6. www.whitehouse.gov EO 14292 (2025)
7. www.sec.gov Ginkgo FY2025 (2025)
8. www.genscript.com GenScript FY2025 (2025)